Fall Quarter Newsletter

Page 1

NEWSLETTER

MY

Fall 2013 Volume 45

It’s Not Guinea Pig Stuff Anymore!

The Pros and Cons of Becoming a Research Subject Dr. Edelman’s Corner

INSIDE Navigating the Maze of a Food Label Page 3

The Grade Study Page 4

Giving Back

I

n order for the pharmaceutical industry and device companies to get their products approved by the Food and Drug Administration (FDA), they have to perform clinical trials with hundreds and often thousands of people at research sites across the United States and around the world.

Page 5

The Jerry Lund Story, Final Interview Page 6

Ask A Pharmacist Page 8

Question of the Month Page 9

A Pathway to Prevention Page 10

Know Your Numbers Page 11

A typical study evaluating a drug for people with type 2 diabetes will involve a placebo, or dummy pill, as well as the actual drug. These types of studies are referred to as “double blinded.” The research subjects, the investigators, and the nursing staff do not know which (the drug or the placebo) was given to each study participant. This eliminates any potential bias and makes the data more meaningful. Before any clinic or institution starts a clinical trial, an official independent body

called the Human Subjects Committee evaluates the study for safety based on early animal and human laboratory studies. Typically, these are done well before the large studies that you hear about. These committees and boards are very strict and will not allow any further study to be performed without the proper precautions in place and prior data showing its safety. In addition to that, each study has an External Data Safety Monitoring Board that has access to the data as the study proceeds Becoming a Research Subject (continued on page 2)


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.